Top News
Treatment-Free Survival Emerges as Novel End Point for Immunotherapy Trials
Clinical Trial Participation May Not Improve Outcomes in Socioeconomically Deprived Areas
Skipping Cancer Referral Appointments Linked to Earlier Death
ASTRO Issues Guideline for Radiation Tx in Pancreatic Cancer
Erleada Approved for Metastatic Castration-Sensitive Prostate Cancer
Evidence Supporting Use of PET/CT Status as a Predictor of Disease Progression in Follicular Lymphoma
Second-Generation CD19 CAR-T Therapy Shows Activity in B-ALL
Electronic Nose Analysis May Predict Response to Anti-PD-1 Therapy in NSCLC
Many Older Patients With AML Not Receiving Active Treatment
EDITORIAL ADVISORY BOARD
E. David Crawford, MD
Jeffrey M. Farma, MD
Featured
-
Dual-Targeted CAR-T Therapies in Solid Tumors: Q&A With Dr Wayne Marasco
Dr Marasco explains that CAR-T therapies are really “cellular therapies that work by way of gene manipulation,” and describes a method through which he hopes CAR-T can produce durable, long-term treatments for solid tumors. -
ESMO Clinical Practice Guidelines for Surveillance of Hereditary Gastrointestinal Cancers
This fact sheet provides an overview of the updated ESMO clinical practice guideline for hereditary GI cancers. -
Certain Anatomical Sites Appear to Respond Well to an Investigational T-Cell Therapy for HPV-Positive Epithelial Cancers
A T-cell therapy that targets a protein only expressed on HPV-positive cancers has shown low toxicity and impressive responses in some patients enrolled in a phase 1/2 clinical trial. -
The DYSF Gene and Renal Cell Carcinoma: A New Prognostic Biomarker?
There is great interest in evaluating the link between hypercalcemia and prognosis in ccRCC by researching the genes that influence calcium levels. -
Implant-Associated Cancers: A Look Beyond Breast Implant-Associated Anaplastic Large Cell Lymphoma
Recent and upcoming case reports suggest possible cases of gluteal and other implant-associated ALCLs, raising questions about the cancer risk across all types of implants. -
Ribociclib Shown to Penetrate the Blood-Brain Barrier in Glioblastoma
A phase 0 study of ribociclib in patients with recurrent glioblastoma seeks to inform the feasibility of the use of CDK 4/6 inhibitors for deadly brain tumors. -
Phase 3 Trial for Oncolytic Viral Therapy Pexa-Vec in Advanced Liver Cancer Terminated Early
Pexa-Vec, in combination with sorafenib, has failed an interim futility analysis, leading to the early termination of the trial.
More Features
The Case for Immunotherapy Trials That Reflect the Real World of Metastatic Melanoma
The problem of low representation of racial minorities is especially urgent during the era of immunotherapy trials.
Treatment Delays With CAR-T Therapy: A High Price to Pay
A treatment delay of 6 months was found to result in up to a 67.3% loss in social value for patients receiving chimeric antigen receptor T-cell therapy.
Microbiome Analysis May Be a Feasible Diagnostic Test for Prostate Cancer
The microbiome could have a role in the diagnosis of PrCa.
Radio-Enhancing Nanoparticles in Sarcoma: Readout of Clinical Outcomes Expected by 2020
Radiation-enhancing particles appear to be a promising tool for improving results with radiotherapy — perhaps even across various cancers.
Recent Advances Offer Paths Forward for Developing Predictive Biomarkers in Cancer Immunotherapy
Recent advances in predictive biomarker development clarify how best to determine PD-L1 expression in tumor cells.
